|
Index of reports
> Cases with Hypotension ()
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Vincristine where reactions include hypotension. The selected reports were submitted to the FDA during the sample period of about a year. Reports 1 - 30 of Next >>
Possible Vincristine side effects in
Reported by a physician from United States on 2012-08-22
Patient:
Reactions: Abdominal Pain, Thrombosis, Hyperkalaemia, Coagulopathy, Hypoglycaemia, Hypocalcaemia, Hypoxia, Hiccups, Alanine Aminotransferase Abnormal, Pneumonitis, Cough, Pain in Extremity, Hypotension, Hyperglycaemia, External Ear Pain, Haematotoxicity, Dehydration, Lower Gastrointestinal Haemorrhage, Hypofibrinogenaemia, Aspartate Aminotransferase Abnormal, Hypokalaemia, Blood Bilirubin Abnormal, Pleural Effusion, Decreased Appetite, Gamma-Glutamyltransferase Abnormal, Hyponatraemia, Hypercalcaemia, Hypophosphataemia, Diarrhoea, Hypoalbuminaemia, Hypertension, Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Dexamethasone
Dosage: 10 mg/m2/day divided in to 2 doses for 14 consecutive days
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Cytarabine
Dosage: on day 1 for all patients and on days 8, 15, 22 for cns invlovment
Indication: Acute Lymphocytic Leukaemia
Methotrexate Sodium
Dosage: 1 dose on day 15 for no cns involvement and on days 8, 15, 22 for cns involvement
Indication: Acute Lymphocytic Leukaemia
Hydrocortisone
Dosage: on days 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Doxorubicin HCL
Dosage: given over 15-30 minutes on day 1
Indication: Acute Lymphocytic Leukaemia
Vincristine
Dosage: 1.5 mg/m2/dose, max. 2 mg, by push on days 1, 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Asparaginase
Dosage: 2500 units/m2/dose as 4 weekly doses
Indication: Acute Lymphocytic Leukaemia
Bortezomib
Dosage: 1.3 mg/sq.m/dose on days 1, 4, 8 and 11 combined with vxld
Indication: Acute Lymphocytic Leukaemia
Other drugs received by patient: Vancomycin; Posaconazole; Voriconazole; Levofloxacin
Possible Vincristine side effects in male
Reported by a physician from United States on 2012-08-21
Patient: male, weighing 13.6 kg (29.9 pounds)
Reactions: Contusion, Vomiting, Flatulence, Hypotension, Tachycardia, Gastrointestinal Necrosis, Cardio-Respiratory Arrest, Hypophagia, Abdominal Distension, Bacterial Test Positive
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cytarabine
Dosage: it 2-2.99 yrs 50 mg
Methotrexate Sodium
Dosage: it 2 mg/m2
PEG-L Asparaginase (Pegaspaegase, Oncospar)
Dosage: iv 2500 units/m2
Vincristine
Dosage: iv 1.5mg/m2 on day 1 and day 8
Dexamethasone TAB
Dosage: po 3 mg/m2 dose (1.75 bid)
Administration route: Oral
Possible Vincristine side effects in female
Reported by a physician from United States on 2012-08-20
Patient: female, weighing 70.8 kg (155.8 pounds)
Reactions: Abdominal Pain, Hyperpyrexia, Anaphylactic Reaction, Chills, Pain, Hepatic Failure, Transaminases Increased, Splenic Infarction, Loss of Consciousness, Aortic Thrombosis, Off Label Use, Malaise, C-Reactive Protein Increased, Myositis, Dyspnoea, Hypotension, Arrhythmia, Lung Consolidation, Hypophosphataemia, Zygomycosis, Bacteraemia, Ventricular Tachycardia, Hyperammonaemia, Neutropenia, Hepatic Infarction, Shock, Infusion Related Reaction
Adverse event resulted in: death, life threatening event
Drug(s) suspected as cause:
Vincristine
Dosage: day 1,8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Start date: 2007-10-23
End date: 2007-10-23
Decadron Phosphate
Dosage: day 1
Indication: Acute Lymphocytic Leukaemia
Start date: 2007-10-23
Velcade
Dosage: day 1, 4, 8 and 11
Indication: Acute Lymphocytic Leukaemia
Start date: 2007-10-23
End date: 2007-10-23
Cytarabine
Dosage: day 1,8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Start date: 2007-10-23
Methotrexate
Dosage: day 1
Indication: Acute Lymphocytic Leukaemia
Start date: 2005-01-01
End date: 2007-01-01
PEG-Asparaginase
Dosage: day 2, 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Start date: 2007-10-25
End date: 2007-10-25
Doxil
Dosage: day 1
Indication: Acute Lymphocytic Leukaemia
Start date: 2007-10-23
End date: 2007-10-23
Possible Vincristine side effects in
Reported by a physician from United States on 2012-08-20
Patient:
Reactions: Abdominal Pain, Thrombosis, Hyperkalaemia, Hypoglycaemia, Coagulopathy, Hypokalaemia, Blood Bilirubin Abnormal, Hiccups, Pleural Effusion, Hypoxia, Hypocalcaemia, Alanine Aminotransferase Abnormal, Cough, Pneumonitis, Decreased Appetite, Pain in Extremity, Hypotension, Hyperglycaemia, Gamma-Glutamyltransferase Abnormal, Hyponatraemia, External Ear Pain, Hypercalcaemia, Haematotoxicity, Hypophosphataemia, Diarrhoea, Dehydration, Hypoalbuminaemia, Lower Gastrointestinal Haemorrhage, Hypertension, Hypofibrinogenaemia, Aspartate Aminotransferase Abnormal, Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Bortezomib
Dosage: 1.3 mg/sq.m/dose on days 1, 4, 8 and 11 combined with vxld
Indication: Acute Lymphocytic Leukaemia
Vincristine
Dosage: 1.5 mg/m2/dose, max. 2 mg, by push on days 1, 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Doxorubicin Hydrochloride
Dosage: given over 15-30 minutes on day 1
Indication: Acute Lymphocytic Leukaemia
Dexamethasone
Dosage: 10 mg/m2/day divided in to 2 doses for 14 consecutive days
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Cytarabine
Dosage: on day 1 for all patients and on days 8, 15, 22 for cns invlovment
Indication: Acute Lymphocytic Leukaemia
Asparaginase
Dosage: 2500 units/m2/dose as 4 weekly doses
Indication: Acute Lymphocytic Leukaemia
Hydrocortisone
Dosage: on days 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Dosage: 1 dose on day 15 for no cns involvement and on days 8, 15, 22 for cns involvement
Indication: Acute Lymphocytic Leukaemia
Other drugs received by patient: Levofloxacin; Voriconazole; Posaconazole; Vancomycin
Possible Vincristine side effects in
Reported by a physician from United States on 2012-08-16
Patient:
Reactions: Off Label Use, Hypotension, Hypertension
Drug(s) suspected as cause:
Cytarabine
Dosage: on day 1 or days 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Dexamethasone
Dosage: per day divided into 2 doses was given orally for 14 consecutive days
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Dosage: on day 15 or days 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Bortezomib
Dosage: per dose on days 1, 4, 8 and 11
Indication: Acute Lymphocytic Leukaemia
Vincristine
Dosage: per dose (2 mg maximum dose) was administered intravenously by push on day 1, 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Hydrocortisone
Dosage: on days 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Doxorubicin Hydrochloride
Dosage: over 15-30 minutes on day 1
Indication: Acute Lymphocytic Leukaemia
PEG-Asparaginase
Dosage: 2500 units/m2/dose was given intramuscularly as 4 weekly doses
Indication: Acute Lymphocytic Leukaemia
Possible Vincristine side effects in
Reported by a physician from United States on 2012-08-14
Patient:
Reactions: Thrombosis, Abdominal Pain, Hyperkalaemia, Hypoglycaemia, Coagulopathy, Hypoxia, Hypocalcaemia, Hiccups, Alanine Aminotransferase Abnormal, Cough, Pneumonitis, Pain in Extremity, Hyperglycaemia, Hypotension, External Ear Pain, Haematotoxicity, Dehydration, Lower Gastrointestinal Haemorrhage, Hypofibrinogenaemia, Aspartate Aminotransferase Abnormal, Hypokalaemia, Neuropathy Peripheral, Blood Bilirubin Abnormal, Pleural Effusion, Decreased Appetite, Hyponatraemia, Gamma-Glutamyltransferase Abnormal, Hypercalcaemia, Hypophosphataemia, Diarrhoea, Hypoalbuminaemia, Hypertension, Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Vincristine
Dosage: 1.5 mg/m2/dose, max. 2 mg, by push on days 1, 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Dosage: 1 dose on day 15 for no cns involvement and on days 8, 15, 22 for cns involvement
Indication: Acute Lymphocytic Leukaemia
Bortezomib
Dosage: 1.3 mg/sq.m/dose on days 1, 4, 8 and 11 combined with vxld
Indication: Acute Lymphocytic Leukaemia
Doxorubicin Hydrochloride
Dosage: given over 15-30 minutes on day 1
Indication: Acute Lymphocytic Leukaemia
Asparaginase
Dosage: 2500 units/m2/dose as 4 weekly doses
Indication: Acute Lymphocytic Leukaemia
Cytarabine
Dosage: on day 1 for all patients and on days 8, 15, 22 for cns invlovment
Indication: Acute Lymphocytic Leukaemia
Hydrocortisone
Dosage: on days 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Dexamethasone
Dosage: 10 mg/m2/day divided in to 2 doses for 14 consecutive days
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Other drugs received by patient: Levofloxacin; Vancomycin; Posaconazole; Voriconazole
Possible Vincristine side effects in female
Reported by a physician from United States on 2012-08-14
Patient: female, weighing 70.8 kg (155.8 pounds)
Reactions: Abdominal Pain, Rhabdomyolysis, Hyperpyrexia, Chills, Anaphylactic Reaction, Bone Pain, Hepatic Failure, Transaminases Increased, Loss of Consciousness, Aortic Thrombosis, Splenic Infarction, Hypokalaemia, Malaise, C-Reactive Protein Increased, Dyspnoea, Hypotension, Hypophosphataemia, Zygomycosis, Bacteraemia, Hyperammonaemia, Neutropenia, Hepatic Infarction, Lung Infiltration, Shock, Infusion Related Reaction
Adverse event resulted in: death, life threatening event, hospitalization
Drug(s) suspected as cause:
Pegaspargase
Dosage: unk, unk
Indication: Acute Lymphocytic Leukaemia
Start date: 2007-10-25
Vincristine
Dosage: 2 mg, unk
Indication: Acute Lymphocytic Leukaemia
Start date: 2007-10-23
End date: 2007-10-23
Doxorubicin HCL
Dosage: 107 mg, unk
Indication: Acute Lymphocytic Leukaemia
Start date: 2007-10-23
End date: 2007-10-23
Cytarabine
Dosage: 70 mg, unk
Indication: Acute Lymphocytic Leukaemia
Start date: 2005-01-01
End date: 2007-10-23
Methotrexate Sodium
Dosage: unk, unk
Indication: Acute Lymphocytic Leukaemia
Start date: 2005-01-01
End date: 2007-01-01
Velcade
Dosage: 1.3 mg/m2, unk
Indication: Acute Lymphocytic Leukaemia
Start date: 2007-10-23
End date: 2007-10-23
Decadron Phosphate
Dosage: 9 mg, unk
Indication: Acute Lymphocytic Leukaemia
Start date: 2007-10-23
End date: 2007-10-23
Possible Vincristine side effects in
Reported by a physician from United Kingdom on 2012-07-27
Patient:
Reactions: Pneumocystis Jiroveci Pneumonia, Neutropenic Sepsis, Hypotension, Dehydration, Pulmonary Oedema, Psittacosis
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Velcade
Dosage: 3.3 mg, unk
Indication: Mantle Cell Lymphoma
Start date: 2008-05-30
End date: 2008-09-03
Doxorubicin Hydrochloride
Dosage: 105 mg, unk
Indication: Mantle Cell Lymphoma
Start date: 2008-05-30
Prednisone
Dosage: 100 mg, unk
Administration route: Oral
Indication: Mantle Cell Lymphoma
Start date: 2008-05-30
Cyclophosphamide
Dosage: 1600 mg, unk
Indication: Mantle Cell Lymphoma
Start date: 2008-05-30
Vincristine
Dosage: 2 mg, unk
Indication: Mantle Cell Lymphoma
Start date: 2008-05-30
Other drugs received by patient: Oramorph SR; Acyclovir; Enoxaparin Sodium; Acyclovir; Acetaminophen; Amitriptyline Hydrochloride; Gabapentin
Possible Vincristine side effects in
Reported by a physician from United Kingdom on 2012-07-17
Patient:
Reactions: Abdominal Pain, Tachycardia, Skin Toxicity, Pyrexia, Fatigue, Neuropathy Peripheral, Hepatotoxicity, Adverse Event, Dizziness, Oedema, Hallucination, Vomiting, Nausea, Gastrointestinal Toxicity, Neutropenic Sepsis, Nephropathy Toxic, Hypotension, Condition Aggravated, Adult T-Cell Lymphoma / Leukaemia, Mucosal Inflammation, Lung Disorder, Infection, Infusion Related Reaction
Adverse event resulted in: death
Drug(s) suspected as cause:
Hydrocortisone
Indication: Adult T-Cell Lymphoma / Leukaemia
Doxorubicin HCL
Dosage: on day 1 of 21 day, (cycle 1-5)
Cytarabine
Indication: Adult T-Cell Lymphoma / Leukaemia
Cyclophosphamide
Dosage: on day 1 of 21 day cycle, (cycle 1-5)
Indication: Adult T-Cell Lymphoma / Leukaemia
Zenapax
Dosage: on days 7 and 14 on cycle 1 of 21 day cycle
Indication: Adult T-Cell Lymphoma / Leukaemia
Vincristine
Dosage: (maximum 2 mg) on day 1 of 21 day cycle, (cycle 1-5)
Indication: Adult T-Cell Lymphoma / Leukaemia
Prednisolone
Dosage: on days 1-5 of 21 day cycle, (cycle 1-5)
Administration route: Oral
Indication: Adult T-Cell Lymphoma / Leukaemia
Methotrexate
Indication: Adult T-Cell Lymphoma / Leukaemia
Radiotherapy
Indication: Adult T-Cell Lymphoma / Leukaemia
Doxorubicin HCL
Dosage: on day 1 of 21 day, (cycle 1-5)
Indication: Adult T-Cell Lymphoma / Leukaemia
Other drugs received by patient: Acyclovir; Thiabendazole; Cotrim; Itraconazole
Possible Vincristine side effects in male
Reported by a physician from United States on 2012-07-16
Patient: male, weighing 27.7 kg (60.9 pounds)
Reactions: Hypotension, Tachycardia, Respiratory Distress, Heart Rate Decreased, Pulmonary Oedema, Septic Shock, Oxygen Saturation Decreased, Pulseless Electrical Activity
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Dexamethasone
Dosage: 78 mg
Methotrexate
Dosage: 15 mg
PEG-L-Asparaginase (Pegaspargase, Oncospar) 2500 IU
Dosage: 2500iu
Cytarabine
Dosage: 70 mg
Vincristine
Dosage: 3 mg
Possible Vincristine side effects in
Reported by a physician from United Kingdom on 2012-07-10
Patient:
Reactions: Abdominal Pain, Skin Toxicity, Tachycardia, Pyrexia, Fatigue, Neuropathy Peripheral, Hepatotoxicity, Adverse Event, Oedema, Dizziness, Hallucination, Vomiting, Gastrointestinal Toxicity, Nausea, Neutropenic Sepsis, Nephropathy Toxic, Hypotension, Adult T-Cell Lymphoma / Leukaemia, Condition Aggravated, Mucosal Inflammation, Lung Disorder, Infection, Infusion Related Reaction
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: on day 1 of 21 day cycle, (cycle 1-5)
Indication: Adult T-Cell Lymphoma / Leukaemia
Prednisolone
Dosage: on days 1-5 of 21 day cycle, (cycle 1-5)
Administration route: Oral
Indication: Adult T-Cell Lymphoma / Leukaemia
Cytarabine
Indication: Adult T-Cell Lymphoma / Leukaemia
Doxorubicin HCL
Dosage: on day 1 of 21 day, (cycle 1-5)
Indication: Adult T-Cell Lymphoma / Leukaemia
Vincristine
Dosage: (maximum 2 mg) on day 1 of 21 day cycle, (cycle 1-5)
Indication: Adult T-Cell Lymphoma / Leukaemia
Methotrexate
Indication: Adult T-Cell Lymphoma / Leukaemia
Zenapax
Dosage: on days 7 and 14 on cycle 1 of 21 day cycle
Indication: Adult T-Cell Lymphoma / Leukaemia
Hydrocortisone
Indication: Adult T-Cell Lymphoma / Leukaemia
Radiotherapy
Indication: Adult T-Cell Lymphoma / Leukaemia
Other drugs received by patient: Cotrim; Itraconazole; Thiabendazole; Acyclovir
Possible Vincristine side effects in
Reported by a health professional (non-physician/pharmacist) from China on 2012-07-02
Patient:
Reactions: Hypotension, Bone Marrow Failure, Rash, Diffuse Large B-Cell Lymphoma, Herpes Zoster, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Ifosfamide
Indication: Diffuse Large B-Cell Lymphoma
Daunorubicin HCL
Indication: Diffuse Large B-Cell Lymphoma
Cisplatin
Indication: Diffuse Large B-Cell Lymphoma
Bortezomib
Dosage: at day 8
Etoposide
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin Hydrochloride
Indication: Diffuse Large B-Cell Lymphoma
Cytarabine
Indication: Diffuse Large B-Cell Lymphoma
Bortezomib
Dosage: day 1 (12 hr before chemotherapy)
Indication: Diffuse Large B-Cell Lymphoma
Prednisone
Indication: Diffuse Large B-Cell Lymphoma
Dexamethasone
Indication: Diffuse Large B-Cell Lymphoma
Cyclophosphamide
Indication: Diffuse Large B-Cell Lymphoma
Carboplatin
Indication: Diffuse Large B-Cell Lymphoma
Possible Vincristine side effects in female
Reported by a physician from Germany on 2012-06-28
Patient: female
Reactions: White Blood Cell Count Decreased, C-Reactive Protein Increased, Sepsis, Hypotension, Presyncope, Neutropenia, Thrombocytopenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Vincristine
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Cyclophosphamide
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Doxorubicin HCL
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Mabthera
Indication: B-Cell Lymphoma
Start date: 2012-04-25
Neulasta
Dosage: daily dose 6 mg, 2 x(29 apr 2012+17 may 2012
Indication: B-Cell Lymphoma
Start date: 2012-04-29
Prednisolone
Dosage: frequency 1 times in 2 week for 5 days
Indication: B-Cell Lymphoma
Start date: 2012-04-26
End date: 2012-04-30
Other drugs received by patient: Enoxaparin Natrium; Aspirin; Ramipril; Tiotropium Bromide; Nebivolol; Torsemide; Pantoprazole; Levothyroxine Sodium; Acyclovir; Simvastatin; Trimethoprim + Sulfamethoxazole
Possible Vincristine side effects in 14 year old female
Reported by a physician from United States on 2012-06-28
Patient: 14 year old female, weighing 60.4 kg (132.9 pounds)
Reactions: Stomatitis, Hypotension, Encephalopathy, Acidosis, Hypercalcaemia, Respiratory Failure, Sepsis, Posterior Reversible Encephalopathy Syndrome, Hypocalcaemia, Enterocolitis, Cardiac Arrest
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Ambisome
Dosage: unk
Indication: Candida Test Positive
Start date: 2012-05-20
Dexamethasone Sodium Phosphate
Dosage: 10 mg/m2, bid or iv on days 1-5 and 15-19
Administration route: Oral
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-04-30
Mitoxantrone Hydrochloride
Dosage: 10 mg/m2, over 30 minutes on days 1 and 2
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-04-30
Pegaspargase
Dosage: 2500 iu/m2 over 1 hr on days 3 and 17
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-04-30
Cefepime
Dosage: unk
Indication: Klebsiella Infection
Start date: 2012-05-10
Vincristine
Dosage: 1.5 mg/m2 cyclic (max 2 mg) over i-5 minutes or infusion via mini bag on days 1, 8, i5 and 22
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-04-30
Calcium Gluconate
Methotrexate
Dosage: 8-15 mg (age based dosing) it on days 1 (or up to 72 hours prior to day 1) and 8
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-04-30
Temsirolimus
Dosage: 7.5 mg/m2, over 30 minutes on days i, 8 and 15 (max dose: 15 mg)
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-04-30
Possible Vincristine side effects in female
Reported by a health professional (non-physician/pharmacist) from Germany on 2012-06-26
Patient: female
Reactions: Syncope, Sepsis, Hypotension, Neutropenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 1493 m
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Neulasta
Indication: B-Cell Lymphoma
Start date: 2012-04-29
Rituximab
Indication: B-Cell Lymphoma
Start date: 2012-04-25
Doxorubicin HCL
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Prednisolone
Indication: B-Cell Lymphoma
Start date: 2012-04-26
End date: 2012-04-30
Vincristine
Dosage: 3.94 m
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Other drugs received by patient: Simvastatin; Levothyroxine; Ramipril; Acyclovir; Acetylsalicylic Acid SRT; Enoxaparin Sodium; Tiotropium Bromide; Trimethoprim + Sulfamethoxazole; Torsemide; Pantoprazole; Nebivolol
Possible Vincristine side effects in female
Reported by a physician from United Kingdom on 2012-05-29
Patient: female, weighing 46.3 kg (101.9 pounds)
Reactions: Death, Metapneumovirus Infection, Hypotension, Cytomegalovirus Infection, Oxygen Supplementation, Neutropenia, Infection
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 1150 mg, once
Indication: T-Cell Lymphoma
Start date: 2011-11-21
End date: 2012-03-20
Mabcampath
Dosage: 30 mg, once on day 1 and 3
Indication: T-Cell Lymphoma
Start date: 2011-12-07
End date: 2012-03-22
Vincristine
Dosage: 2 mg, once
Indication: T-Cell Lymphoma
Start date: 2011-11-21
End date: 2012-03-20
Prednisolone
Dosage: 100 mg, day 1-5
Administration route: Oral
Indication: T-Cell Lymphoma
Start date: 2011-11-21
End date: 2012-03-20
Doxorubicin HCL
Dosage: 75 mg, once
Indication: T-Cell Lymphoma
Start date: 2011-11-21
End date: 2012-03-20
Other drugs received by patient: Lansoprazole; Valganciclovir; Levothyroxine Sodium; Motilium; Lenograstim; Ondansetron; Enoxaparin; Cotrim
Possible Vincristine side effects in 56 year old female
Reported by a individual with unspecified qualification from Germany on 2012-05-17
Patient: 56 year old female
Reactions: Hypotension
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Indication: non-Hodgkin's Lymphoma Unspecified Histology Aggressive
Mabthera
Indication: non-Hodgkin's Lymphoma Unspecified Histology Aggressive
Vincristine
Indication: non-Hodgkin's Lymphoma Unspecified Histology Aggressive
Prednisone
Indication: non-Hodgkin's Lymphoma Unspecified Histology Aggressive
Doxorubicin HCL
Indication: non-Hodgkin's Lymphoma Unspecified Histology Aggressive
Possible Vincristine side effects in 18 year old male
Reported by a physician from United States on 2012-05-10
Patient: 18 year old male, weighing 126.4 kg (278.1 pounds)
Reactions: Abdominal Pain, White Blood Cell Count Decreased, Hypotension, Hyponatraemia, Acidosis, Capillary Leak Syndrome, Sepsis, Platelet Count Decreased
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Pegaspargase
Dosage: 2500 iu, cyclic
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-25
End date: 2012-03-02
Velcade
Dosage: 1.3 mg/m2, cyclic
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-24
End date: 2012-03-02
Vincristine
Dosage: 2 mg, cyclic
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-24
End date: 2012-03-02
Prednisone TAB
Dosage: 50 mg, bid
Administration route: Oral
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-24
End date: 2012-03-04
Methotrexate
Dosage: unk
Indication: B Precursor Type Acute Leukaemia
Hydrocortisone
Dosage: unk
Indication: B Precursor Type Acute Leukaemia
Cytarabine
Dosage: 70 mg, cyclic
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-24
Doxorubicin HCL
Dosage: 60 mg/m2, cyclic
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-24
End date: 2012-02-24
Possible Vincristine side effects in 17 year old male
Reported by a physician from United States on 2012-04-25
Patient: 17 year old male, weighing 45.0 kg (99.0 pounds)
Reactions: Back Pain, Gastrointestinal Haemorrhage, Hypotension, Malnutrition, Neoplasm Progression, Haemorrhoidal Haemorrhage, Convulsion, Leukaemia, Cachexia, Diarrhoea, NO Therapeutic Response, Sepsis, Nervous System Disorder, Altered State of Consciousness
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Methotrexate
Dosage: ;x1;inth
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-03-05
End date: 2012-03-05
Methotrexate
Dosage: ;x1;inth
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-20
End date: 2012-02-20
Cytarabine
Dosage: ;x1;inth
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-20
End date: 2012-02-20
Prednisone
Dosage: 20 mg/m**2; po
Administration route: Oral
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-20
End date: 2012-03-14
Vincristine
Dosage: 1.5 mg/m**2;x1;iv
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-20
End date: 2012-02-20
Vincristine
Dosage: 1.5 mg/m**2;x1;iv
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-03-12
End date: 2012-03-12
Oncaspar
Dosage: 2500 iu/m**2;qw;im
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-20
End date: 2012-03-12
Doxorubicin HCL
Dosage: 60 ug/m**2;x1;iv
Indication: B Precursor Type Acute Leukaemia
Velcade
Dosage: 1.3 mg/m**2;x1;iv
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-20
End date: 2012-02-20
Other drugs received by patient: Keppra
Possible Vincristine side effects in 18 year old male
Reported by a consumer/non-health professional from United States on 2012-04-13
Patient: 18 year old male, weighing 126.4 kg (278.1 pounds)
Reactions: Abdominal Pain, White Blood Cell Count Decreased, Hypotension, Hyponatraemia, Acidosis, Capillary Leak Syndrome, Sepsis, Platelet Count Decreased
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Vincristine
Dosage: 2 mg, cyclic
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-24
End date: 2012-03-02
Prednisone TAB
Dosage: 50 mg, bid
Administration route: Oral
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-24
End date: 2012-03-04
Hydrocortisone
Dosage: unk
Indication: B Precursor Type Acute Leukaemia
Pegaspargase
Dosage: 2500 iu, cyclic
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-25
End date: 2012-03-02
Cytarabine
Dosage: 70 mg, cyclic
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-24
Doxorubicin HCL
Dosage: 60 mg/m2, cyclic
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-24
End date: 2012-02-24
Velcade
Dosage: 1.3 mg/m2, cyclic
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-24
End date: 2012-03-02
Methotrexate
Dosage: unk
Indication: B Precursor Type Acute Leukaemia
Possible Vincristine side effects in male
Reported by a physician from United States on 2012-04-13
Patient: male, weighing 63.0 kg (138.7 pounds)
Reactions: Atelectasis, Cardiomegaly, Malaise, Fatigue, Oral Candidiasis, Hypocalcaemia, Pleural Effusion, Dizziness, Pulmonary Oedema, Blood Sodium Decreased, White Blood Cell Count Decreased, Pneumonia, Hypotension, Anaemia, Supraventricular Tachycardia, Toxicity To Various Agents, Lobar Pneumonia, Escherichia Test Positive, Blood Potassium Decreased, Heart Rate Increased, Dehydration, Hypophagia, Platelet Count Decreased, Neutropenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Doxorubicin HCL
Dosage: 50 mg/m2, on day 1 of a 21-day cycle
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2009-01-23
End date: 2009-03-13
Prednisone TAB
Dosage: 100 mg, on days 1 through 5 of a 21-day cycle
Administration route: Oral
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2009-01-23
End date: 2009-03-13
Rituximab
Dosage: 375 mg/m2, on day 1 of a 21-day cycle
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2009-01-23
End date: 2009-03-13
Enzastaurine
Dosage: 1125 mg, loading dose, on day 2
Administration route: Oral
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2009-01-24
End date: 2009-01-24
Vincristine
Dosage: 1.4 mg/m2, on day 1 of a 21-day cycle
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2009-01-23
End date: 2009-03-13
Cyclophosphamide
Dosage: 750 mg/m2, on day 1 of a 21-day cycle
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2009-01-23
End date: 2009-03-13
Enzastaurine
Dosage: 500 mg, daily
Administration route: Oral
Start date: 2009-01-25
End date: 2009-03-19
Other drugs received by patient: Hydromorphone; Marinol; Megestrol; Prednisone; Fentanyl; Zofran; Omeprazole; Iron
Possible Vincristine side effects in 78 year old female
Reported by a health professional (non-physician/pharmacist) from Japan on 2012-04-11
Patient: 78 year old female
Reactions: Hypovolaemic Shock, Dysphagia, Colitis Ulcerative, Haemorrhage, Hypotension, Faeces Discoloured, Abdominal Tenderness, Abdominal Discomfort, Mucosal Ulceration, Fatigue, Decreased Appetite
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Vincristine
Dosage: 2 mg, unk
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin HCL
Indication: Diffuse Large B-Cell Lymphoma
Rituximab
Dosage: 375 mg/m2, unk
Indication: Diffuse Large B-Cell Lymphoma
Cyclophosphamide
Dosage: 750 mg/m2, unk
Indication: Diffuse Large B-Cell Lymphoma
Prednisolone
Indication: Diffuse Large B-Cell Lymphoma
Possible Vincristine side effects in 10 year old female
Reported by a physician from United States on 2012-04-05
Patient: 10 year old female, weighing 20.8 kg (45.8 pounds)
Reactions: Abdominal Pain, Headache, Caecitis, Hypokalaemia, Fungaemia, Hypoxia, Rash Pustular, Back Pain, Nausea, Pain in Extremity, Hypotension, Hyponatraemia, Febrile Neutropenia, Hypophosphataemia, Respiratory Tract Infection, Neuralgia, Enterocolitis Infectious
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Prednisone
Dosage: 20 mg/m2, cyclic
Administration route: Oral
Indication: B Precursor Type Acute Leukaemia
Start date: 2011-12-14
End date: 2011-12-27
Doxorubicin HCL
Dosage: 60 mg/m2, cyclic
Indication: B Precursor Type Acute Leukaemia
Start date: 2011-12-14
End date: 2011-12-14
Cytarabine
Dosage: unk
Indication: B Precursor Type Acute Leukaemia
End date: 2011-12-29
Pegaspargase
Dosage: unk
Indication: B Precursor Type Acute Leukaemia
Start date: 2011-12-15
End date: 2011-12-29
Vincristine
Dosage: 1.5 mg/m2, cyclic
Indication: B Precursor Type Acute Leukaemia
Start date: 2011-12-14
End date: 2011-12-29
Methotrexate
Dosage: unk
Indication: B Precursor Type Acute Leukaemia
End date: 2011-12-29
Velcade
Dosage: 1.3 mg/m2, cyclic
Indication: B Precursor Type Acute Leukaemia
Start date: 2011-12-14
End date: 2011-12-17
Hydrocortisone
Dosage: unk
Indication: B Precursor Type Acute Leukaemia
End date: 2011-12-29
Possible Vincristine side effects in 78 year old female
Reported by a health professional (non-physician/pharmacist) from Japan on 2012-04-04
Patient: 78 year old female
Reactions: Hypovolaemic Shock, Dysphagia, Colitis Ulcerative, Haemorrhage, Hypotension, Faeces Discoloured, Abdominal Tenderness, Abdominal Discomfort, Mucosal Ulceration, Fatigue, Decreased Appetite
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Doxorubicin HCL
Indication: Diffuse Large B-Cell Lymphoma
Rituximab
Dosage: 375 mg/m2, unk
Indication: Diffuse Large B-Cell Lymphoma
Prednisolone
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Dosage: 2 mg, unk
Indication: Diffuse Large B-Cell Lymphoma
Cyclophosphamide
Dosage: 750 mg/m2, unk
Indication: Diffuse Large B-Cell Lymphoma
Possible Vincristine side effects in 18 year old male
Reported by a physician from United States on 2012-04-03
Patient: 18 year old male, weighing 126.4 kg (278.1 pounds)
Reactions: White Blood Cell Count Decreased, Abdominal Pain, Metabolic Acidosis, Clostridium Test Positive, Urine Output Decreased, Hypotension, Hyponatraemia, Capillary Leak Syndrome, Platelet Count Decreased, Septic Shock
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Oncaspar
Dosage: 2500 iu;x1;iv
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-02-24
End date: 2012-03-02
Doxorubicin HCL
Dosage: 60 mg/m**2;x1;iv
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-02-24
End date: 2012-02-24
Velcade
Dosage: 1.3 mg/m**2; qd; iv
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-02-24
End date: 2012-03-02
Vincristine
Dosage: 1.5 mg/m**2;qd;iv
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-02-24
End date: 2012-03-02
Prednisone TAB
Dosage: 20 mg/m**2;qd;po
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-02-24
End date: 2012-03-04
Cytarabine
Dosage: 70 mg;x1;inth
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-02-24
Hydrocortisone
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Dosage: inth
Indication: Acute Lymphocytic Leukaemia
Possible Vincristine side effects in 75 year old male
Reported by a consumer/non-health professional from United States on 2012-03-20
Patient: 75 year old male, weighing 63.0 kg (138.6 pounds)
Reactions: Fatigue, Anaemia, Hypotension, Dehydration, Neutropenia, Lobar Pneumonia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Vincristine
Dosage: on day 1 every 21 days first dose: 23-jan-09-13mar09(50days)
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2009-03-13
End date: 2009-03-13
Doxorubicin HCL
Dosage: on day 1 every 21 days first dose: 23-jan-09-13mar09(50days)
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2009-03-13
End date: 2009-03-13
Prednisone
Dosage: on days 1 through 5 every 21 days first dose: 23-jan-09-13mar09(50days)
Administration route: Oral
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2009-03-13
End date: 2009-03-13
Enzastaurin
Dosage: loading dose(1st):1125mg on 24jan09 25jan09-13mar09(48d):500mg;po on hold since 19mar09(54 days)
Administration route: Oral
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2009-03-19
Cyclophosphamide
Dosage: on day 1 every 21 days first dose: 23-jan-09-13mar09(50days)
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2009-03-13
End date: 2009-03-13
Rituximab
Dosage: on day 1 every 21 days first dose: 23-jan-09-13mar09(50days)
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2009-03-19
End date: 2009-03-19
Other drugs received by patient: Megestrol Acetate; Zofran; Dronabinol; Fentanyl; Iron; Hydromorphone HCL; Marinol; Omeprazole
Possible Vincristine side effects in male
Reported by a physician from United States on 2012-03-19
Patient: male, weighing 63.0 kg (138.7 pounds)
Reactions: Pneumonia, Fatigue, Hypotension, Dehydration, Anaemia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Vincristine
Dosage: 1.4 mg/m2, on day 1 of a 21-day cycle
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2009-01-23
End date: 2009-03-13
Cyclophosphamide
Dosage: 750 mg/m2, on day 1 of a 21-day cycle
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2009-01-23
End date: 2009-03-13
Enzastaurine
Dosage: 500 mg, daily
Administration route: Oral
Start date: 2009-01-25
End date: 2009-03-19
Rituximab
Dosage: 375 mg/m2, on day 1 of a 21-day cycle
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2009-01-23
End date: 2009-03-13
Doxorubicin HCL
Dosage: 50 mg/m2, on day 1 of a 21-day cycle
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2009-01-23
End date: 2009-03-13
Enzastaurine
Dosage: 1125 mg, loading dose, on day 2
Administration route: Oral
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2009-01-24
End date: 2009-01-24
Prednisone TAB
Dosage: 100 mg, on days 1 through 5 of a 21-day cycle
Administration route: Oral
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2009-01-23
End date: 2009-03-13
Other drugs received by patient: Fentanyl; Omeprazole; Prednisone; Zofran; Hydromorphone; Megestrol; Iron; Marinol
Possible Vincristine side effects in 18 year old male
Reported by a consumer/non-health professional from United States on 2012-03-13
Patient: 18 year old male, weighing 126.4 kg (278.1 pounds)
Reactions: Abdominal Pain, White Blood Cell Count Decreased, Hypotension, Hyponatraemia, Acidosis, Capillary Leak Syndrome, Sepsis, Platelet Count Decreased
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Doxorubicin HCL
Dosage: 60 mg/m2, cyclic
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-24
End date: 2012-02-24
Vincristine
Dosage: 1.5 mg/m2, cyclic
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-24
End date: 2012-03-02
Velcade
Dosage: 1.3 mg/m2, cyclic
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-24
End date: 2012-03-02
Cytarabine
Dosage: 70 mg, cyclic
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-24
Pegaspargase
Dosage: 2500 iu, cyclic
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-24
End date: 2012-03-02
Methotrexate
Dosage: unk
Indication: B Precursor Type Acute Leukaemia
Prednisone TAB
Dosage: 20 mg/m2, cyclic
Administration route: Oral
Indication: B Precursor Type Acute Leukaemia
Start date: 2012-02-24
End date: 2012-03-04
Hydrocortisone
Dosage: unk
Indication: B Precursor Type Acute Leukaemia
Possible Vincristine side effects in male
Reported by a physician from United States on 2012-03-12
Patient: male, weighing 63.0 kg (138.6 pounds)
Reactions: Atelectasis, Pneumonia, Dyspnoea, Hypotension, Supraventricular Tachycardia, Anaemia, Cardiomegaly, Fatigue, Oral Candidiasis, Dehydration, Heart Rate Increased, Hypocalcaemia, Pleural Effusion, Dizziness, Neutropenia, Escherichia Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Prednisone TAB
Dosage: 1125 mg
Administration route: Oral
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2009-01-24
End date: 2009-01-24
Vincristine
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2009-01-23
End date: 2009-03-13
Rituximab
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2009-01-23
End date: 2009-03-13
Doxorubicin HCL
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2009-01-23
End date: 2009-03-13
Prednisone
Administration route: Oral
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2009-01-23
End date: 2009-03-13
Prednisone TAB
Dosage: 500 mg
Administration route: Oral
Start date: 2009-01-25
End date: 2009-03-19
Cyclophosphamide
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2009-01-23
End date: 2009-03-13
Other drugs received by patient: Hydromorphone HCL; MD Anderson Mouthwash; Iron; Prednisone; Megestrol Acetate; Omeprazole; Zofran; Fentanyl; Marinol
Possible Vincristine side effects in 10 year old female
Reported by a consumer/non-health professional from United States on 2012-03-09
Patient: 10 year old female, weighing 20.8 kg (45.8 pounds)
Reactions: Abdominal Pain, Confusional State, Lung Infection, Headache, Peripheral Sensory Neuropathy, Caecitis, Hypokalaemia, Fungaemia, Hypoxia, Clostridial Infection, Back Pain, Rash Pustular, Vomiting, Nausea, Pain in Extremity, Lung Neoplasm, Hypotension, Febrile Neutropenia, Pancytopenia, Hyponatraemia, Hypophosphataemia, Diarrhoea, NO Therapeutic Response, Sepsis, Hypophagia, Respiratory Tract Infection, Enterocolitis Infectious, Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Pegaspargase
Dosage: unk
Indication: B Precursor Type Acute Leukaemia
Start date: 2011-12-15
End date: 2011-12-29
Doxorubicin HCL
Dosage: 60 mg/m2, cyclic
Indication: B Precursor Type Acute Leukaemia
Start date: 2011-12-14
End date: 2011-12-14
Prednisone
Dosage: 20 mg/m2, cyclic
Administration route: Oral
Indication: B Precursor Type Acute Leukaemia
Start date: 2011-12-14
End date: 2011-12-27
Methotrexate
Dosage: unk
Indication: B Precursor Type Acute Leukaemia
End date: 2011-12-29
Vincristine
Dosage: 1.5 mg/m2, cyclic
Indication: B Precursor Type Acute Leukaemia
Start date: 2011-12-14
End date: 2011-12-29
Cytarabine
Dosage: unk
Indication: B Precursor Type Acute Leukaemia
End date: 2011-12-29
Hydrocortisone
Dosage: unk
Indication: B Precursor Type Acute Leukaemia
End date: 2011-12-29
Velcade
Dosage: 1.3 mg/m2, cyclic
Indication: B Precursor Type Acute Leukaemia
Start date: 2011-12-14
End date: 2011-12-17
Page 1 Next >>
|
